Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5718 in Proteinuric Chronic Kidney Disease (FLAIR)
NCT04492722Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of atuliflapon in chronic kidney disease (CKD), sponsored by AstraZeneca. Started Oct 2020; status: terminated.
02
Drugs
atuliflapon
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04492722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04492722.